Adagene to Participate in Two Investor Conferences in September
Adagene (Nasdaq: ADAG), a company focused on antibody-based therapy development, announced its participation in two upcoming investor conferences in New York this September.
The company's Chief Strategy Officer, Mickael Chane-Du, will attend the H.C. Wainwright Global Investment Conference on September 8 at 11:00 AM ET and the Morgan Stanley Global Healthcare Conference on September 10 at 7:00 AM ET. Both events will feature fireside chats and one-on-one investor meetings.
Webcasts of the presentations will be available on Adagene's website for 30 days following the events.
Adagene (Nasdaq: ADAG), società impegnata nello sviluppo di terapie a base di anticorpi, ha annunciato la sua partecipazione a due conferenze per investitori che si terranno a New York questo settembre.
Il Chief Strategy Officer Mickael Chane-Du parteciperà all'H.C. Wainwright Global Investment Conference l'8 settembre alle 11:00 ET e alla Morgan Stanley Global Healthcare Conference il 10 settembre alle 7:00 ET. Entrambi gli eventi prevedono sessioni "fireside chat" e incontri one-to-one con investitori.
Le webcast delle presentazioni saranno disponibili sul sito di Adagene per 30 giorni dopo gli eventi.
Adagene (Nasdaq: ADAG), una empresa dedicada al desarrollo de terapias basadas en anticuerpos, anunció su participación en dos conferencias para inversores que se celebrarán en Nueva York este septiembre.
El Chief Strategy Officer, Mickael Chane-Du, asistirá al H.C. Wainwright Global Investment Conference el 8 de septiembre a las 11:00 ET y al Morgan Stanley Global Healthcare Conference el 10 de septiembre a las 7:00 ET. Ambos eventos incluirán charlas tipo "fireside" y reuniones individuales con inversores.
Las transmisiones web de las presentaciones estarán disponibles en la web de Adagene durante 30 días después de los eventos.
Adagene (Nasdaq: ADAG)는 항체 기반 치료제 개발에 주력하는 기업으로, 이번 9월 뉴욕에서 열리는 투자자 콘퍼런스 두 곳에 참가한다고 발표했습니다.
전략총괄책임자(Chief Strategy Officer) Mickael Chane-Du는 9월 8일 오전 11:00(ET)에 열리는 H.C. Wainwright Global Investment Conference와 9월 10일 오전 7:00(ET)에 열리는 Morgan Stanley Global Healthcare Conference에 참석합니다. 두 행사 모두 파이어사이드 채팅과 1:1 투자자 미팅이 예정되어 있습니다.
발표의 웹캐스트는 행사 후 30일간 Adagene 웹사이트에서 시청할 수 있습니다.
Adagene (Nasdaq: ADAG), une société spécialisée dans le développement de thérapies à base d'anticorps, a annoncé sa participation à deux conférences investisseurs qui auront lieu à New York en septembre.
Le Chief Strategy Officer, Mickael Chane-Du, assistera à la H.C. Wainwright Global Investment Conference le 8 septembre à 11h00 ET et à la Morgan Stanley Global Healthcare Conference le 10 septembre à 7h00 ET. Les deux événements incluront des "fireside chats" ainsi que des rencontres individuelles avec des investisseurs.
Les webcasts des présentations seront accessibles sur le site d'Adagene pendant 30 jours après les événements.
Adagene (Nasdaq: ADAG), ein Unternehmen, das sich auf die Entwicklung von Antikörper-basierten Therapien konzentriert, gab seine Teilnahme an zwei Investorenkonferenzen in New York im September bekannt.
Der Chief Strategy Officer Mickael Chane-Du wird an der H.C. Wainwright Global Investment Conference am 8. September um 11:00 Uhr ET und an der Morgan Stanley Global Healthcare Conference am 10. September um 07:00 Uhr ET teilnehmen. Beide Veranstaltungen umfassen Fireside-Chats und Einzelgespräche mit Investoren.
Webcasts der Präsentationen werden auf der Adagene-Website für 30 Tage nach den Veranstaltungen verfügbar sein.
- None.
- None.
SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at two investor conferences in September, both taking place in New York, New York.
H.C. Wainwright 27th Annual Global Investment Conference
- Fireside Chat Date: Monday, September 8
- Fireside Chat Time: 11:00 AM (Eastern Time)
- Location: Lotte New York Palace Hotel
- Webcast: https://journey.ct.events/view/5c4a1cf5-b8ef-4b48-ae46-3a0f5912b3ca
Morgan Stanley 23rd Annual Global Healthcare Conference
- Fireside Chat Date: Wednesday, September 10
- Fireside Chat Time: 7:00 AM (Eastern Time)
- Location: Sheraton New York Times Square Hotel
- Webcast: https://cc.webcasts.com/morg007/090825a_js/?entity=139_6SK4L3R
A webcast of the presentations will be accessible in the Investors section of the company’s website at https://www.adagene.com for at least 30 days.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science.
Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues.
Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multi-specific T-cell engagers.
For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and X.
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Investor Contacts:
Raymond Tam
raymond_tam@adagene.com
Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com
FAQ
When is Adagene (ADAG) presenting at the H.C. Wainwright Conference in September 2025?
When is Adagene's presentation at the Morgan Stanley Healthcare Conference 2025?
Who will represent Adagene (ADAG) at the September 2025 investor conferences?
How can investors access Adagene's conference presentations?
